Publicaciones en las que colabora con Juan María González Lahoz (29)

2010

  1. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  2. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  3. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

2009

  1. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  2. Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

    AIDS, Vol. 22, Núm. 18, pp. 2535-2537

  3. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

2007

  1. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

  3. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

    AIDS, Vol. 21, Núm. 1, pp. 41-46

  4. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 11, pp. 1374-1376

2006

  1. Gene polymorphisms, isoenzyme activity, and emergence of resistance to efavirenz

    Contagion: Reports, Cases, and Commentaries in HIV and Infectious Disease Research, Vol. 3, Núm. 1, pp. 18-22

  2. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1

    Clinical Infectious Diseases, Vol. 42, Núm. 2, pp. 291-295

2005

  1. Clinical benefit of interventions driven by therapeutic drug monitoring

    HIV Medicine, Vol. 6, Núm. 5, pp. 360-365

  2. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis c virus-coinfected patients

    Journal of Acquired Immune Deficiency Syndromes, Vol. 39, Núm. 4, pp. 401-405

  3. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

    Clinical Infectious Diseases, Vol. 40, Núm. 9, pp. 1358-1361

2004

  1. Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection

    AIDS Research and Human Retroviruses, Vol. 20, Núm. 7, pp. 698-700

  2. Predictors of virological response to Atazanavir in protease inhibitor-experienced patients

    HIV Clinical Trials, Vol. 5, Núm. 4, pp. 201-205

2003

  1. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

    AIDS Patient Care and STDs, Vol. 17, Núm. 9, pp. 443-445

  2. Diarrhea related to lopinavir is most often mild and not related to plasma drug levels [3]

    Journal of Acquired Immune Deficiency Syndromes